ENA Respiratory Attracts US$22.4m (AU$34m) to Fund Phase II

Written by

admin

in

MELBOURNE, Australia, Oct. 22, 2025 (GLOBE NEWSWIRE) — ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defense enhancers to minimize the impact of symptomatic viral respiratory infections, announces today…

Continue Reading

More posts